Pineo G F, Hull R D
University of Calgary, Calgary General Hospital, Alberta, Canada.
Drugs. 1996 Jul;52(1):71-92. doi: 10.2165/00003495-199652010-00006.
All patients at moderate to high risk for the development of venous thromboembolism should receive prophylaxis. The approaches of proven value include low dose heparin, low molecular weight heparin, oral anticoagulants and intermittent pneumatic compression. The use of one of the cited heparin nomograms will ensure that all patients are rapidly brought within the therapeutic range. Because of the varying sensitivities of thromboplastins, each laboratory should establish a therapeutic range using the activated partial thromboplastin time (APTT) which will correspond to 0.2 to 0.4 U/ml of heparin. Constant vigilance and a high level of suspicion are necessary to establish the clinical diagnosis of heparin-induced thrombocytopenia, and to institute appropriate therapy. Physicians should be aware of the sensitivity of the thromboplastin being used in the performance of the International Normalised Ratio (INR). Care must be taken to ensure that patients are maintained within the target therapeutic range for INR (in most cases 2 to 3) by frequent determination of the INR and appropriate adjustments of warfarin dosage. Low molecular weight heparin is the recommended approach to the initial management of venous thromboembolism where these agents are available. Patients with an acute episode of venous thromboembolism should receive warfarin therapy for at least 3 months. At the present time it is reasonable to treat the first recurrence with oral anticoagulants for a period of 12 months and indefinitely for more than 1 recurrence. For selected patients with acute massive pulmonary embolism, thrombolytic therapy with one of the available agents is recommended. However, the role of thrombolytic therapy in patients with proximal venous thrombosis remains unclear. In selected patients with acute venous thromboembolism who have contraindications to anticoagulant therapy or who-have objectively documented recurrent disease while on adequate therapy, the insertion of an inferior vena cava filter is recommended.
所有有中度至高度静脉血栓栓塞发生风险的患者均应接受预防治疗。已证实有价值的方法包括低剂量肝素、低分子量肝素、口服抗凝剂和间歇性充气加压。使用其中一种引用的肝素剂量图表将确保所有患者迅速达到治疗范围。由于凝血活酶的敏感性不同,每个实验室应使用活化部分凝血活酶时间(APTT)建立一个与0.2至0.4 U/ml肝素相对应的治疗范围。要确立肝素诱导的血小板减少症的临床诊断并进行适当治疗,持续的警惕和高度的怀疑是必要的。医生应了解在进行国际标准化比值(INR)检测时所使用凝血活酶的敏感性。必须注意通过频繁测定INR并适当调整华法林剂量,确保患者维持在INR的目标治疗范围内(大多数情况下为2至3)。在有低分子量肝素可用的情况下,低分子量肝素是静脉血栓栓塞初始治疗的推荐方法。急性静脉血栓栓塞发作的患者应接受华法林治疗至少3个月。目前,对于首次复发,用口服抗凝剂治疗12个月是合理的,对于复发超过1次的情况则应无限期治疗。对于选定的急性大面积肺栓塞患者,推荐使用一种可用药物进行溶栓治疗。然而,溶栓治疗在近端静脉血栓形成患者中的作用仍不明确。对于有抗凝治疗禁忌证或在充分治疗时有客观记录的复发性疾病的选定急性静脉血栓栓塞患者,推荐插入下腔静脉滤器。